Eravacycline - CAS 1207283-85-9

Eravacycline (CAT: I006700) is a synthetic tetracycline antibiotic developed for the treatment of bacterial infections. It belongs to the class of antibiotics known as tetracyclines and specifically targets the ribosome, inhibiting protein synthesis in bacteria. Eravacycline has broad-spectrum activity against both Gram-positive and Gram-negative bacteria, including multidrug-resistant strains such as methicillin-resistant Staphylococcus aureus (MRSA) and carbapenem-resistant Enterobacteriaceae (CRE). It has demonstrated efficacy in treating complicated intra-abdominal infections and complicated urinary tract infections in clinical trials. Eravacycline offers a potential therapeutic option for infections caused by resistant bacteria, contributing to the ongoing efforts to combat antibiotic resistance.

Catalog Number: I006700

CAS Number: 1207283-85-9

PubChem Substance ID:355036148

Molecular Formula: C27H31FN4O8

Molecular Weight:558.56

Purity: ≥95%

* For research use only. Not for human or veterinary use.


SynonymsTP-434; TP 434; TP434; Eravacycline;(4S,4aS,5aR,12aS)-4-(Dimethylamino)-7-fluoro-3,10,12,12a-tetrahydroxy-1,11-dioxo-9-((pyrrolidin-1-ylacetyl)amino)-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide


Molecular Formula: C27H31FN4O8
Molecular Weight558.56
SolubilitySoluble in DMSO, not in water
StorageDry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Overview of Clinical ResearchOriginator: Tetraphase Pharmaceuticals<br /> Class: Acetamides; Antibacterials; Pyrrolidines; Small molecules; Tetracyclines<br /> Mechanism of Action: Protein 30S ribosomal subunit inhibitors<br /> Orphan Drug Status: No<br /> New Molecular Entity: Yes<br /> Highest Development Phases: Phase III Urinary tract infections

Computed Descriptor

IUPAC Name(4S,4aS,5aR,12aR)-4-(dimethylamino)-7-fluoro-1,10,11,12a-tetrahydroxy-3,12-dioxo-9-[(2-pyrrolidin-1-ylacetyl)amino]-4a,5,5a,6-tetrahydro-4H-tetracene-2-carboxamide